What makes p-tau217 superior to p-tau181 and p-tau231 as an Alzheimer's blood biomarker?

Author : jack smith | Published On : 06 May 2026

The NULISAseq™ Neuro 220 Panel leverages ultra-sensitive detection to quantify biomarkers like p-tau217 in blood, enabling earlier, more precise detection of Alzheimer’s pathology in a scalable, multiplex format.

https://alamarbio.com/alamar-biosciences-launches-nulisaseq-neuro-220-panel-to-advance-neurodegenerative-disease-research/

p-tau217 is considered superior to p-tau181 and p-tau231 as an Alzheimer’s blood biomarker because it shows higher diagnostic accuracy, stronger correlation with amyloid and tau pathology, and larger signal changes between healthy and diseased states. Studies consistently demonstrate that p-tau217 better differentiates Alzheimer’s disease from other neurodegenerative conditions and tracks disease progression more reliably than p-tau181, while also offering robust early detection capabilities alongside p-tau231.